Related by context. All words. (Click for frequent words.) 77 diagnosed glioblastoma multiforme 76 diagnosed chronic myeloid 74 diagnosed GBM 74 diagnosed glioblastoma 73 phase Ph + 72 diagnosed multiple myeloma 70 CML CP 70 diagnosed Glioblastoma multiforme 69 myelodysplastic myeloproliferative diseases 68 leukemia AML 68 relapsed MM 68 Philadelphia Chromosome Positive 67 Kit CD# positive 67 chronic myeloid 67 chronic eosinophilic leukemia 67 Ph + CP 66 hypereosinophilic syndrome 66 Pharmacokinetics PK 66 unresectable recurrent 66 non splenectomized 66 diagnosed GBM concomitantly 66 Relapsed Refractory 65 Hodgkin lymphoma HL 65 systemic juvenile idiopathic 65 Ph + acute lymphoblastic 65 eosinophilic asthma 65 Peginterferon alfa 2b 65 Callisto initiated 65 refractory chronic lymphocytic 65 primary hypercholesterolemia 65 relapsed refractory 64 humanized therapeutic 64 Annamycin 64 rheumatoid arthritis psoriatic arthritis 64 Nilotinib 64 controlled dose escalation 64 Ph + ALL 64 oropharyngeal candidiasis OPC 64 HER2 positive metastatic breast 64 Clofarabine 64 VEGFR2 inhibitor 64 autoantibody positive 64 dasatinib Sprycel 64 CYT# potent vascular disrupting 64 essential thrombocythemia ET 64 hematological cancers notably 64 Ribavirin causes 64 non myeloid malignancies 63 humanized interleukin 6 63 heavily pretreated 63 chronic idiopathic thrombocytopenic purpura 63 non metastatic osteosarcoma 63 chronic immune thrombocytopenic 63 relapsing remitting MS RRMS 63 decompensated liver disease 63 purpura ITP 63 progressive PsA 63 antibody MAb 63 RoACTEMRA 63 untreated de novo 63 achieved CCyR 63 dasatinib Sprycel ® 63 lintuzumab SGN 63 relapsed leukemia 63 psoriatic arthritis PsA 63 hormone refractory metastatic prostate 63 leukemia CML 63 lenalidomide Revlimid R 63 relapsed refractory AML 63 Complicated Skin 63 Acute Myeloid Leukemia AML 63 receptor tyrosine kinase inhibitor 63 Bayer HealthCare Onyx Pharmaceuticals 63 selective modulator 63 BCG refractory carcinoma 63 selective phosphodiesterase 63 lymphoid malignancies 63 Testosterone MDTS R 63 aggressive systemic mastocytosis 63 de novo kidney transplant 63 imatinib Gleevec ® 63 CHOP chemotherapy 63 LymphoStat B belimumab 62 Systemic Juvenile Idiopathic 62 alfa 2a 62 SJIA 62 metastatic hormone refractory 62 Treatment Experienced 62 Ofatumumab 62 blinded randomized placebo controlled 62 Dementia Related Psychosis 62 receiving immunosuppressive therapy 62 indolent follicular non 62 novel VDA molecule 62 polycythemia vera essential thrombocythemia 62 untreated AML 62 PEGylated Fab fragment 62 Peginterferon 62 metastatic malignant 62 remission induction 62 patients coinfected 62 recurrent glioblastoma multiforme 62 BCR ABL inhibitor 62 hyperphenylalaninemia HPA due 62 evaluating mipomersen 62 evaluating tivozanib 62 cutaneous T 62 Chronic Myeloid Leukemia 62 relapsed refractory multiple myeloma 62 lymphoid blast 62 onset diabetes mellitus 62 acyclovir Lauriad R 62 onset idiopathic hypogonadism 62 rituximab refractory 62 systemic anaplastic large 62 Newly Diagnosed Multiple Myeloma 62 juvenile idiopathic arthritis JIA 62 melphalan prednisone 62 treatment naive genotype 62 LHRH receptor positive 62 refractory chronic myeloid 62 refractory metastatic colorectal cancer 62 BRIM2 62 demonstrated antitumor activity 62 treatment naïve genotype 62 vapreotide acetate 62 thetreatment 62 Bosutinib 62 relapsed acute lymphoblastic 61 INSPIRE Trial Phase III 61 homozygous familial hypercholesterolemia 61 previously untreated follicular 61 leukemia CLL 61 Chronic lymphocytic leukemia CLL 61 Hypoactive Sexual Desire Disorder 61 infliximab monotherapy 61 untreated metastatic pancreatic 61 systemic lupus erythematosus SLE 61 rALLy 61 By JENNIFER LEARN 61 Bcr Abl T#I mutation 61 Chronic Lymphocytic Leukemia CLL 61 pediatric Crohn disease 61 8mg/kg 61 phase IIb study 61 idiopathic thrombocytopenic purpura ITP 61 acute myeloid 61 unstable angina UA 61 relapsed ALL 61 TNF Tumor Necrosis Factor 61 refractory NSCLC 61 Chronic lymphocytic leukemia 61 adalimumab Humira 61 papillary renal cell carcinoma 61 Letairis ambrisentan 61 partial onset seizures 61 patientswith 61 Budesonide foam crofelemer 61 erlotinib Tarceva ® 61 Ph + CML 61 somatostatin analog 61 metastatic androgen independent 61 achieved ACR# 61 de novo AML 61 primary generalized tonic 61 leukemia multiple myeloma 61 Lpl Financial Corp 61 Atypical Hemolytic Uremic Syndrome 61 refractory cutaneous T 61 Naive Patients 61 oral sapacitabine 61 kidney urologic 61 SPRYCEL ® 61 leukemia ALL 61 rituximab refractory follicular 61 Sapacitabine 61 approved incretin mimetic 61 IMiDs ® 61 reduce serum phosphate 61 refractory indolent non 61 brand ciclesonide HFA 61 biologic therapy 61 Omacetaxine 61 dosing cohort 61 Voreloxin 61 gemcitabine Gemzar ® 61 High Dose quadruples 61 SinuNase TM 61 Syndrome LEMS 61 Follicular Lymphoma 61 MKC# MT 61 ACTEMRA TM 61 myelodysplastic syndrome MDS 61 relapsed mantle 61 sorafenib Nexavar ® 61 opioid naive 61 Meets Primary Endpoint 61 Completes Patient Enrollment 61 recurrent metastatic 61 rALLy clinical trial 61 MKC# MKC# PP 60 PLX STROKE targeting 60 galiximab 60 Albuferon TM 60 TEMODAL 60 topical gel formulation 60 antiretroviral naïve 60 Juvenile Idiopathic Arthritis 60 metastatic pancreatic 60 FLT3 mutations 60 everolimus tablets 60 pegylated interferon alfa 2a 60 chronic myeloid leukemia CML 60 TTR amyloidosis 60 Gamunex C 60 developing Bicifadine serotonin 60 Gleevec resistant 60 PEGylated anti 60 Lambert Eaton Myasthenic 60 dexamethasone Decadron 60 Certolizumab pegol 60 smoldering multiple myeloma 60 metastatic dermatofibrosarcoma protuberans DFSP 60 ABSSSI 60 Ophena TM 60 oral nucleoside analogue 60 refractory acute myeloid 60 Hormone Refractory Prostate Cancer 60 ritonavir boosted 60 placebo controlled dose escalation 60 targeted biologic therapies 60 Systemic Sclerosis 60 Brentuximab Vedotin SGN 60 orally administered inhibitor 60 schizophrenia schizoaffective disorder 60 acute myelogenous leukemia AML 60 Lymphocytic 60 Paclitaxel Carboplatin 60 Crohn disease CD 60 Randomized Phase 60 Acute lymphoblastic leukemia 60 untreated multiple myeloma 60 Mg Usa 60 HBeAg positive 60 IMiDs ® compound 60 Initiates Enrollment 60 Leukemia AML 60 Heterozygous Familial Hypercholesterolemia 60 metastatic castrate resistant 60 Pegasys ® 60 metastatic renal cell carcinoma 60 Chronic Idiopathic Constipation 60 recombinant PSMA vaccine 60 non metastatic resectable 60 Multiple Ascending Dose 60 Fludarabine 60 acadesine 60 candidates Azedra TM 60 bone marrow reticulin deposition 60 Cutaneous T 60 Cloretazine 60 chronic plaque psoriasis 60 Refractory Hodgkin Lymphoma 60 either acutely decompensated 60 sodium glucose cotransporter 60 Nonalcoholic fatty liver 60 stage IIIb IV 60 Crofelemer budesonide foam 60 XL# anticancer compounds 60 Temsirolimus 60 orally administered synthetic retinoid 60 Acute lymphocytic leukemia 60 relapsing multiple sclerosis 60 heFH 60 Relapsing Remitting Multiple Sclerosis 60 Treatment Naïve 60 NOMID 60 injectable biologic 60 metastatic colorectal carcinoma 60 stage IIIb 60 HIV HCV coinfected 60 protease inhibitor PI 60 Relapsed Multiple Myeloma 60 IMPDH inhibitor 60 number NCT# ClinicalTrials.gov 60 YONDELIS 60 vinca alkaloid 60 HBeAg negative 60 Phase Ib IIa 60 Adjunctive Therapy 60 AVASTIN 60 AML MDS 60 albiglutide 60 PNP inhibitor 60 Raptiva ® 60 refractory Ph + 60 refractory anaplastic astrocytoma 60 Bronchiectasis 60 FOLFOX6 chemotherapy regimen 60 Soft Tissue Sarcoma 60 neovascular form 60 cell lymphoma CTCL 60 vWD 60 haematologic 60 registrational Phase 60 atypical hemolytic uremic syndrome 60 blinded placebo controlled 60 Hsp# Inhibitor 60 IBS C 60 PRN FDA Approves 59 Denufosol 59 pan histone deacetylase 59 TYGACIL 59 Phase #b/#a trial 59 Elotuzumab 59 Tanespimycin 59 plus COPEGUS 59 RANK Ligand inhibitor 59 3TC lamivudine Epivir 59 Acute Attacks 59 rheumatoid arthritis RA psoriatic 59 Bezielle 59 accumulate preferentially 59 Atripla combines 59 chronic granulomatous disease 59 anti EGFR antibody 59 Leukemias 59 advanced unresectable 59 Previously Treated 59 anthracycline containing 59 use transdermal sumatriptan 59 indolent NHL 59 nucleoside naive 59 histologically confirmed 59 gastrointestinal stromal tumors 59 Tocilizumab 59 concomitant cardiac 59 cell acute lymphoblastic 59 telaprevir dosed 59 dopamine partial agonist 59 receiving INTRON 59 imatinib resistant 59 5 fluorouracil leucovorin 59 generation purine nucleoside 59 severe oral mucositis 59 acute leukemias 59 toenail onychomycosis 59 mg administered orally 59 ® lenalidomide 59 personalized dendritic cell 59 systemic ALCL 59 Trial Evaluating 59 Shows Efficacy 59 estramustine 59 lymphoid cancers 59 anthracycline taxane 59 combining voreloxin 59 symptomatic BPH 59 Elagolix 59 standard chemotherapy regimen 59 Epratuzumab 59 subependymal giant cell 59 SNT MC# 59 visilizumab 59 metastatic renal 59 Phase IIb Trial 59 Triapine 59 Lennox Gastaut Syndrome 59 advanced metastatic renal 59 CYP#A# CYP#D# 59 receptor inhibitor 59 chronic HCV genotype 59 Phase 2b Clinical Trial 59 Edurant 59 Myelofibrosis 59 naïve HCV 59 mRCC 59 weekly subcutaneous injections 59 mGluR2 positive 59 TO AVOID PREGNANCY WHILE 59 bortezomib Velcade R 59 Blinatumomab 59 small molecule Hedgehog 59 metastatic renal cell 59 sorafenib Nexavar 59 castrate resistant prostate cancer 59 Granted Orphan Drug 59 Traficet EN 59 Neovascular AMD 59 constipation OIC 59 PRTX 59 Chronic ITP 59 Improves Outcomes 59 compound INCB# 59 LHON 59 idiopathic thrombocytopenic purpura 59 Previously Untreated 59 Vidaza ® 59 refractory unresponsive 59 non mutated KRAS 59 AAG geldanamycin analog 59 R lenalidomide 59 dacarbazine DTIC 59 unique alkylating agent 59 PEGINTRON TM 59 Recurrent Glioblastoma 59 elacytarabine 59 PD LID 59 Dose Escalation 59 cell chronic lymphocytic 59 named Gryposaurus monumentensis 59 cetuximab Erbitux R 59 selectively inhibited 59 mildly symptomatic 59 Treatment Naive Patients 59 Sodium oxybate 59 memantine HCl 59 potentially hepatotoxic 59 humanised monoclonal antibody 59 Perifosine KRX 59 superficial bladder cancer 59 dimebon latrepirdine 59 Severe Sepsis 59 CYP#A# substrate 59 Polymerase Inhibitor 59 T2DM 58 gastrointestinal stromal tumor GIST 58 Personalized Immunotherapy 58 Ceflatonin R 58 Pivotal Phase III 58 dyskinesia PD LID 58 Adalimumab 58 oral rivaroxaban 58 CTAP# Capsules 58 REVIVE Diabetes 58 hypomethylating agents 58 Sprycel dasatinib 58 sunitinib malate 58 GetGoal Phase III 58 achieved sustained virologic 58 Renal Impairment 58 ritonavir boosted protease inhibitor 58 JAK2 Inhibitor 58 colesevelam HCl 58 Firdapse TM amifampridine phosphate 58 sorafenib Nexavar R 58 dose escalation clinical 58 Myelodysplastic Syndrome MDS 58 thalidomide Thalomid 58 KRAS wild 58 chronic HBV 58 ErbB2 positive 58 oral ghrelin agonist 58 NPM1 mutations 58 resistant hormone refractory 58 Fludara ® 58 intravenous RSD# 58 neutropenia dehydration dyspnea 58 cystic fibrosis bronchiectasis 58 pediatric acute lymphoblastic 58 tyrosine kinase inhibitor TKI 58 Campath alemtuzumab 58 initiated Phase Ib 58 PKC# 58 Fingolimod 58 polyarticular 58 biliary tract cancer 58 Cariprazine 58 deep venous thromboses 58 nucleoside analogue 58 Diffuse Large B 58 Investigational Treatment 58 untreated metastatic colorectal 58 immune thrombocytopenic purpura ITP 58 recurrent malignant glioma 58 Amrubicin 58 chronic HCV infection 58 atypical Hemolytic Uremic Syndrome 58 Mantle Cell Lymphoma 58 YOUR LOCAL ANIMAL SHELTER 58 Pooled Analysis 58 Evoltra ® 58 CTAP# 58 Folfox 58 granted Orphan Drug 58 Relapsed Refractory Aggressive 58 developed preclinically 58 underwent resection 58 dirucotide MBP# 58 Pegloticase 58 refractory metastatic 58 Vicinium TM 58 BARACLUDE ® 58 metastatic gastric 58 Golimumab 58 forodesine 58 administered concomitantly 58 Vitrasert R 58 Pathway Inhibitor 58 imatinib therapy 58 Darunavir 58 venlafaxine XR 58 Lupus Nephritis 58 cytidine nucleoside analog 58 evaluating picoplatin 58 virologically suppressed 58 REYATAZ r arm 58 HBeAg positive patients 58 Intravitreal 58 diabetes mellitus DM 58 docetaxel Taxotere R 58 ribavirin therapy 58 CIMZIA ™ 58 post herpetic neuralgia PHN 58 myeloproliferative neoplasms 58 unresectable Stage III 58 mixed hyperlipidemia 58 R Saizen R 58 follicular lymphoma FL 58 relapsing remitting multiple sclerosis 58 ORENCIA ® 58 atopic asthma 58 mutated K ras 58 FUSILEV enhances 58 Completes Enrollment 58 relapsed Acute Myeloid 58 complement inhibitor eculizumab 58 cytarabine daunorubicin 58 Temodar ® 58 familial amyloidotic polyneuropathy FAP 58 BCG vaccinated 58 pregabalin Lyrica 58 Combination REOLYSIN R 58 gastrointestinal stromal 58 substantially excreted 58 golimumab CNTO 58 phase IIb clinical 58 leukopenia pancytopenia thrombocytopenia 58 Copegus ® ribavirin 58 MDS AML 58 smoldering myeloma 58 Demonstrates Significant 58 catheter occlusion 58 Rheumatoid Arthritis RA 58 TMC# C# 58 Simulect 58 BRIM3 58 cell carcinoma RCC 58 AVN# Phase 58 Patients Treated With 58 K ras mutations 58 irinotecan doxorubicin oxaliplatin paclitaxel 58 Romiplostim 58 CAELYX 58 Vidaza azacitidine 58 chronic lymphocytic leukemia CLL 58 diffuse gastric 58 relapsed myeloma 58 CIMZIA r certolizumab pegol 58 Secondary Hyperparathyroidism 58 Chronic Myelogenous Leukemia 58 castration resistant hormone refractory 58 Ceflatonin 58 Cytarabine Liposome Injection 58 Monotherapy 58 Quinamed 58 ceftazidime 58 Dermylex TM 58 hyperplasia BPH 58 refractory colorectal cancer 58 interferon gamma 1b 58 Abrupt discontinuation 58 atherothrombotic events 58 Presents Positive 58 Chronic Hepatitis C 58 sorafenib tablets 58 CIMZIA TM certolizumab pegol 58 holdovers Felix Hernandez 58 PREZISTA r 58 precursor acute lymphoblastic 58 IRX 2 58 GH deficiency 58 CTA# Injection 58 metastatic colorectal 58 Vidaza R 58 Aflibercept 58 advanced medullary thyroid 58 Acute Exacerbations 58 Adjuvant Treatment 58 Dasatinib 58 Amgen Neulasta R 58 virus HCV protease inhibitor 58 pegylated interferon alpha 58 denileukin diftitox 58 GENASIS 58 nonalcoholic steatohepatitis NASH 58 directed radiotherapeutic antibody 58 plus prednisone prednisolone 58 Acute Myeloid Leukaemia AML 58 C1 INH deficiency 58 tumors GIST 58 pyrexia mucositis sepsis febrile 58 MEK Inhibitor 58 pharmacologically active isomer 58 desvenlafaxine succinate 58 Amgen Neulasta ® 58 relapsed multiple myeloma 57 INVANZ 57 Phase IIb trials 57 Tasimelteon 57 myocardial infarction ventricular fibrillation 57 KRAS mutations occur 57 FOLFOX6 57 transcriptase inhibitor NNRTI 57 CD4 monoclonal antibody 57 systemic invasive fungal 57 Laquinimod 57 underwent surgical resection 57 CCR9 antagonist 57 Chronic Heart Failure 57 serologically active systemic lupus 57 Oral Fingolimod 57 Bevacizumab Avastin 57 Castration Resistant Prostate Cancer 57 included exfoliative dermatitis 57 nucleoside analog 57 basal cell carcinoma BCC 57 immune thrombocytopenic purpura 57 histone deacetylase HDAC inhibitor 57 refractory Hodgkin 57 taxane refractory 57 ribavirin RBV 57 BRAF V# mutation 57 mcg kg REBETOL 57 unresectable stage 57 mTOR inhibitor 57 Lenalidomide 57 receiving VELCADE 57 Alemtuzumab 57 AA Amyloidosis 57 Hospital Acquired Pneumonia 57 approved successor Simponi 57 CLL SLL 57 initiate Phase IIa 57 Initiate Phase 57 Plicera 57 gefitinib Iressa 57 MCyR 57 B CLL 57 Myelodysplastic syndromes 57 biologic DMARD 57 ZACTIMA 57 Tarceva TM 57 recurrent metastatic ovarian cancer 57 Chronic myeloid leukemia 57 receiving XGEVA 57 MAGE A3 ASCI 57 VFEND 57 shingles vaccine Zostavax 57 STELARA TM 57 Ultra Midcap# Proshares 57 HoFH 57 phase Ib 57 dosing cohorts 57 mitoxantrone plus 57 anaplastic astrocytoma 57 assessing T DM1 57 Chronic Myelogenous Leukemia CML 57 Bendamustine 57 EOquin TM phase 57 severe malignant osteopetrosis 57 TTF Therapy 57 Begins Dosing 57 YONDELIS R 57 IIa trial 57 HCD# [002] 57 certolizumab 57 steroid refractory ulcerative 57 opioid induced constipation OIC 57 methotrexate therapy 57 R rilonacept Injection 57 TNF alpha selectively neutralizing 57 novel nucleoside analog 57 CCR5 antagonist 57 personalized cellular immunotherapy 57 AGILECT R 57 exocrine pancreatic insufficiency EPI 57 cisplatin gemcitabine 57 Lennox Gastaut syndrome 57 Achieves Primary Endpoint 57 FEMALES SHOULD BE ADVISED 57 GW# [003] 57 Zorbtive TM 57 Plicera TM 57 null responder 57 TNF Blockers 57 interferon beta 1a infertility 57 alefacept 57 Clinical Trial Evaluating 57 4SC AG ISIN DE# 57 Mg Uk 57 Natalizumab 57 achieved sustained virological 57 COPEGUS ribavirin 57 herpes zoster shingles 57 immunocompetent 57 Antitumor Activity 57 cancer mCRC 57 RhuDex R 57 Gemzar ® 57 dose dose escalation 57 investigational monoclonal antibody 57 acute myeloid leukemia AML 57 lymphoma CTCL 57 xanthine oxidase inhibitor 57 rubella hepatitis 57 prospectively enrolled 57 recurrent glioblastoma 57 sunitinib Sutent ® 57 Cell Lymphoma 57 Ovitrelle R Serostim 57 Humanized Anti 57 PROSTVAC ® 57 myeloid metaplasia 57 recurrent NSCLC 57 investigational oral 57 docetaxel Taxotere ® 57 5 HT1A receptor 57 hepatocellular carcinomas 57 albiglutide currently 57 chronic thromboembolic pulmonary 57 Azacitidine 57 2 methoxyestradiol 57 ovarian endometrial 57 induced macular edema 57 methylnaltrexone bromide 57 CD# CEA 57 minimally symptomatic 57 hypertrichosis occurred 57 RET PTC rearrangements 57 leukemia lymphoma multiple myeloma 57 mCRC patients 57 CC genotype 57 MCSP respectively 57 Systemic Lupus Erythematosus SLE 57 inhaled corticosteroid ICS 57 cyclophosphamide doxorubicin vincristine 57 DEB# 57 Stage IIIB IV 57 non CF bronchiectasis 57 alvespimycin 57 nucleotide analog 57 TRANSFORMS 57 RhuDex ™ 57 Viread tenofovir disoproxil fumarate 57 pediatric glioma 57 vinorelbine tartrate 57 Aryplase 57 Gastrointestinal Stromal Tumors 57 plus methotrexate 57 oral levofloxacin 57 HGS ETR1 mapatumumab 57 dose intramuscular 57 Bucindolol 57 dimeglumine 57 canakinumab 57 polycythemia vera PV 57 Glioblastoma Multiforme 57 pralatrexate injection folate analogue 57 CLL8 57 oral antidiabetic medication 57 achieve sustained virologic 57 Tumor Necrosis Factor 57 Vildagliptin 57 myelodysplastic syndromes MDS 57 Demonstrates Positive 57 Acute myeloid leukemia 57 Kuvan R 57 azilsartan medoxomil 57 nucleotide analogue 57 del 5q MDS 57 metastatic castration resistant 57 anti TNF alpha 57 NOXAFIL 57 systemic JIA 57 IIa clinical trials 57 Advanced Renal Cell 57 progressive psoriatic arthritis 57 Curis collaborator Genentech 57 NMIBC 57 acute GvHD 57 gastrointestinal stromal tumors GISTs 57 lamivudine resistant 57 multiple myeloma MM 57 Physician Insights 57 HeFH 57 Tykhe Capital Llc 57 follicular Non Hodgkin 57 PORxin TM platforms 57 HIV uninfected 57 RezularTM 57 mGluR5 NAM 57 Arzerra ofatumumab 57 stage IIIB 57 valsartan amlodipine 57 Namenda Memantine HCl 57 leukemia APL 57 #mg/m# [001] 57 class mGluR5 inhibitor 57 HCV SPRINT 57 metastatic carcinoid 57 metastatic bladder 57 rash pruritus nausea 57 prokinetic agent 57 Ozarelix 57 patients undergoing percutaneous 57 aged ≥ 57 taxane chemotherapy administered 57 idiopathic PAH 57 chimeric monoclonal antibody 57 stable angina pectoris 57 PI3K/Akt pathway inhibitor 57 nilotinib Tasigna ® 57 ZOLINZA 57 Newly Diagnosed Patients 57 dasatinib 57 Hepatocellular Carcinoma HCC 57 Study Evaluating 57 cause mesothelioma asbestosis 57 Hedgehog Pathway Inhibitor 57 Anthracycline 57 prostate cancer HRPC 57 L Annamycin 57 vitreoretinal disorders 57 % CI #.#-#.# [003] 57 raloxifene Evista 57 hA# 57 Paraplatin ® carboplatin 57 plus dacarbazine 57 Is Well Tolerated 57 evaluating Xcytrin 57 acute mania 57 paclitaxel poliglumex 57 plus dexamethasone 56 CIMZIA TM 56 Relapsed Refractory Multiple Myeloma 56 REMINYL ® 56 ara C 56 prednisone prednisolone plus 56 refractory myeloma 56 lupus nephritis 56 mild vasodilator 56 Waldenstrom macroglobulinemia 56 alemtuzumab Campath 56 HIV coinfected 56 delivers fluocinolone acetonide FA 56 baminercept 56 serotonin norepinephrine reuptake inhibitor 56 mg/m2 administered 56 rheumatoid arthritis osteoarthritis ankylosing 56 predominantly classic subfoveal 56 Chronic Lymphocytic Leukemia 56 Irinotecan 56 Subgroup Analysis 56 MabCampath 56 phase IIb trial 56 chronic myelogenous leukemia CML 56 MGd 56 Luteinizing Hormone Releasing Hormone 56 FluCAM arm 56 T#I mutation 56 primary humoral immunodeficiency 56 Riversource Large Cap 56 Prospective Randomized 56 4mg/kg 56 adult chronic ITP 56 Aeolus Pharmaceuticals Announces 56 receiving highly emetogenic 56 idiopathic Parkinson disease 56 liposomal formulation 56 homozygous FH 56 monoclonal antibody conjugated 56 vaccine RiVax TM 56 onset seizures 56 insulin glulisine 56 azacitidine 56 Patients Receiving 56 Lubiprostone 56 Velcade bortezomib 56 immunocompetent adults 56 acetonide FA 56 Metastatic Colorectal Cancer 56 fallopian tube carcinoma 56 vascular occlusive diseases 56 relapsed SCLC 56 oral proteasome inhibitor 56 Glioblastoma Multiforme GBM 56 Decitabine 56 hypercholesterolemic patients 56 RRMS patients 56 bendamustine 56 rilonacept 56 Pertuzumab 56 Vicriviroc 56 completely resected 56 CVP cyclophosphamide vincristine 56 chronic periodontitis 56 dual endothelin receptor antagonist 56 common hematologic malignancy 56 Flu Cy 56 Maribavir 56 idarubicin 56 demethylation agents 56 hepatitis C HCV 56 glioblastoma multiforme GBM 56 headache abdominal pain 56 p# biomarker 56 Pivotal Study 56 Talabostat 56 Hepsera adefovir dipivoxil 56 Prolongs Survival 56 castrate resistant 56 myelofibrosis MF 56 Myelodysplastic Syndromes MDS 56 CINQUIL 56 HCV RESPOND 2 56 systemic sclerosis SSc 56 iloprost synthetic compound 56 Tipranavir 56 recurrent genital herpes 56 osteosarcomas 56 Non Hodgkin 56 diabetic neuropathic pain 56 NR2B selective 56 RhuDex TM 56 cyclophosphamide FC 56 Pralatrexate 56 tenofovir emtricitabine 56 Peginterferon Alfa 2a 56 HIV seronegative 56 Phase #b/#a clinical 56 radiation chemoradiation 56 Cerebral Amyloid Angiopathy 56 basal cell nevus syndrome 56 evaluating Actimmune 56 imatinib Gleevec 56 gemtuzumab ozogamicin 56 CCR5 tropic HIV 56 administered intranasally 56 Epothilone D 56 trabectedin 56 mg q#h 56 metastatic GIST 56 systemic lupus erythematosus 56 disease modifying antirheumatic 56 Raptiva r 56 progressive neurodegenerative 56 neutropenic sepsis 56 HER2 + 56 blastic phase 56 TRACON Pharmaceuticals 56 cyclist Adham Sbeih 56 CAMMS# 56 CIMZIA R 56 Idiopathic Pulmonary Fibrosis IPF 56 Major Depressive Disorder MDD 56 myelofibrosis polycythemia vera 56 Xelox 56 sJIA 56 Idiopathic Pulmonary Fibrosis 56 Diabetic Macular Edema 56 epithelial ovarian 56 peritumoral brain edema 56 hoFH 56 tuberous sclerosis TS 56 beclomethasone dipropionate 56 VICTOR E1 56 ofatumumab HuMax CD# 56 omacetaxine mepesuccinate 56 etanercept Enbrel 56 Diamyd r 56 Tasigna nilotinib 56 peginterferon alfa 56 administered intramuscularly 56 receiving CIMZIA #mg 56 chronic rheumatic 56 CVP chemotherapy 56 alpha 2b 56 MVA HPV IL2 56 HLA DR2 56 erlotinib Tarceva R 56 null responder HCV 56 IPF CAPACITY 56 autosomal recessive disorder 56 huN# DM1 56 hypophosphatasia 56 AKT inhibitor 56 investigational integrase inhibitor 56 Pegasys peginterferon alfa 2a